Core Viewpoint - Jinfang Pharmaceutical-B (02595) experienced a significant stock price increase, rising over 8% towards the end of trading, with a current price of 31.1 HKD and a trading volume of 28.08 million HKD [1] Group 1: Clinical Trial Announcement - On November 11, Jinfang Pharmaceutical announced the initiation of a Phase III clinical trial comparing the efficacy and safety/tolerability of GFH375 monotherapy versus investigator-selected chemotherapy for patients with KRAS G12D mutated metastatic pancreatic cancer [1] - The company’s prospectus indicates that GFH375 is being developed as a first-line oral G12D inhibitor, with plans for the monotherapy to enter Phase I/II trials by June 2024 [1] - GFH375/VS-7375 has received FDA Fast Track designation this year, allowing it to be used for both first-line and subsequent treatments of locally advanced and metastatic KRAS G12D mutated PDAC patients [1] Group 2: Early Data Presentation - Early data on GFH375 monotherapy for solid tumors was presented at prestigious international academic conferences such as ASCO and WCLC this year, through late-breaking abstracts (LBA) and oral presentations [1]
港股异动 | 劲方医药-B(02595)尾盘涨超8% GFH375片启动III期临床 适应症为转移性胰腺癌